Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/6361
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ciaranelloa, Andrea L | - |
dc.contributor.author | Doherty, Kathleen | - |
dc.contributor.author | Penazzato, Martina | - |
dc.contributor.author | Lindsey, Jane C | - |
dc.contributor.author | Harrison, Linda | - |
dc.contributor.author | Kelly, Kathleen | - |
dc.contributor.author | Walensky, Rochelle P | - |
dc.contributor.author | Essajee, Shaffiq | - |
dc.contributor.author | Losina, Elena | - |
dc.contributor.author | Muhe, Lulu | - |
dc.contributor.author | Wools-Kaloustian, Kara | - |
dc.contributor.author | Ayaya, Samuel | - |
dc.contributor.author | Weinstein, Milton C | - |
dc.contributor.author | Freedberg, Kenneth A. | - |
dc.date.accessioned | 2022-05-26T08:35:13Z | - |
dc.date.available | 2022-05-26T08:35:13Z | - |
dc.date.issued | 2015-03-13 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/6361 | - |
dc.description.abstract | Background: The International Maternal, Pediatric, and Adolescent Clinical Trials P1060 trial demonstrated superior outcomes for HIV-infected children less than 3 years old initiating antiretroviral therapy (ART) with lopinavir/ritonavir compared to nevirapine, but lopinavir/ritonavir is four-fold costlier. Design/methods: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-Pediatric model, with published and P1060 data, to project outcomes under three strategies: no ART; first-line nevirapine (with second-line lopinavir/ritonavir); and first-line lopinavir/ritonavir (second-line nevirapine). The base-case examined South African children initiating ART at age 12 months; sensitivity analyses varied all key model parameters. Outcomes included life expectancy, lifetime costs, and incremental cost-effectiveness ratios [ICERs; dollars/year of life saved ($/YLS)]. We considered interventions with ICERs less than 1 per-capita gross domestic product (South Africa: $7500)/YLS as ‘very cost-effective,’ interventions with ICERs below 3 gross domestic product/YLS as ‘cost-effective,’ and interventions leading to longer life expectancy and lower lifetime costs as ‘cost-saving’. Results: Projected life expectancy was 2.8 years with no ART. Both ART regimens markedly improved life expectancy and were very cost-effective, compared to no ART. First-line lopinavir/ritonavir led to longer life expectancy (28.8 years) and lower lifetime costs ($41 350/person, from lower second-line costs) than first-line nevirapine (27.6 years, $44 030). First-line lopinavir/ritonavir remained cost-saving or very cost-effective compared to first-line nevirapine unless: liquid lopinavir/ritonavir led to two-fold higher virologic failure rates or 15-fold greater costs than in the base-case, or second-line ART following first-line lopinavir/ritonavir was very ineffective | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wolter Klower | en_US |
dc.subject | Cost-effectiveness | en_US |
dc.subject | First-line antiretroviral therapy | en_US |
dc.subject | IMPAACT | en_US |
dc.subject | P1060 trial | en_US |
dc.subject | Pediatric HIV | en_US |
dc.title | Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
AYAYA 2.pdf | 562.06 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.